AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
Phase 1
Completed
- Conditions
- Pancreatic Neoplasms
- Interventions
- Drug: KU-0059436 (AZD2281)(PARP inhibitor)
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2013-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 68
- Registration Number
- NCT00515866
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Phase II Efficacy Study of AZD6244 in Colorectal Cancer
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT00514761
- Locations
- 🇧🇷
Research Site, Sao Paulo, Brazil
Be SMART NIS, Moderate to Servere Asthma Patient Observation
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 900
- Registration Number
- NCT00514787
- Locations
- 🇦🇹
Research Site, Vienna, Austria
Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2012-08-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 241
- Registration Number
- NCT00509028
- Locations
- 🇯🇵
Research Site, Takizawa, Iwate, Japan
A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice
Completed
- Conditions
- Bronchial Asthma
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5137
- Registration Number
- NCT00505388
- Locations
- 🇬🇧
Research Site, Welingborough, United Kingdom
Open-label, Safety and Efficacy Study of Pulmicort® Turbuhaler® in Japanese Children With Bronchial Asthma
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2011-08-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT00504062
- Locations
- 🇯🇵
Research Site, Takizawa, Iwate, Japan
Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Metastatic Tumor
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2009-01-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT00503412
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
Phase 1
Completed
- Conditions
- Recurrent GlioblastomaBrain Tumor
- Interventions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2009-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00503204
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2009-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00503477
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART
Completed
- Conditions
- Bronchial Asthma
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00503061
- Locations
- 🇬🇧
Research Site, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath